Archived Press Releases
The news releases presented here were believed to be accurate at the time they were issued and are provided for historical reference purposes only. They contain information that may no longer be accurate. Readers should not rely on the continued accuracy of any such material. All readers should carefully check the dates of issuance of the releases. NeurogesX assumes no obligation and does not intend to update, correct or otherwise modify any of these press releases regarding events that occur after their original release.
- October 18, 2006
NeurogesX Phase 3 Study in Postherpetic Neuralgia Meets Primary Endpoint - September 6, 2006
NeurogesX Extension Study Indicates Repeat Treatment with Transacin Provides Prolonged Pain Reduction in HIV-Associated Neuropathy - August 1, 2006
NeurogesX Receives Confirmation of Transacin Eligibility for EU Centralized Market Submission - June 13, 2006
NeurogesX Completes Enrollment in Pivotal Phase 3 Postherpetic Neuralgia Trial - February 9, 2006
NeurogesX Announces Presentation of Positive Phase 3 Results in Painful HIV-Associated Neuropathy at CROI - January 3, 2006
NeurogesX Appoints Jeffrey Tobias, M.D., as Chief Medical Officer
